Skip to main content
Top
Published in: Pituitary 6/2015

01-12-2015

IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition

Authors: Tirissa J. Reid, Zhezhen Jin, Wei Shen, Carlos M. Reyes-Vidal, Jean Carlos Fernandez, Jeffrey N. Bruce, Jane Kostadinov, Kalmon D. Post, Pamela U. Freda

Published in: Pituitary | Issue 6/2015

Login to get access

Abstract

Purpose

Activity of acromegaly is gauged by levels of GH and IGF-1 and epidemiological studies demonstrate that their normalization reduces acromegaly’s excess mortality rate. However, few data are available linking IGF-1 levels to features of the disease that may relate to cardiovascular (CV) risk. Therefore, we tested the hypothesis that serum IGF-1 levels relative to the upper normal limit relate to insulin sensitivity, serum CV risk markers and body composition in acromegaly.

Methods

In this prospective, cross-sectional study conducted at a pituitary tumor referral center we studied 138 adult acromegaly patients, newly diagnosed and previously treated surgically, with fasting and post-oral glucose levels of endocrine and CV risk markers and body composition assessed by DXA.

Results

Active acromegaly is associated with lower insulin sensitivity, body fat and CRP levels than acromegaly in remission. %ULN IGF-1 strongly predicts insulin sensitivity, better than GH and this persists after adjustment for body fat and lean tissue mass. %ULN IGF-1 also relates inversely to CRP levels and fat mass, positively to lean tissue and skeletal muscle estimated (SME) by DXA, but not to blood pressure, lipids, BMI or waist circumference. Gender interacts with the IGF-1-lean tissue mass relationship.

Conclusions

Active acromegaly presents a unique combination of features associated with CV risk, reduced insulin sensitivity yet lower body fat and lower levels of some serum CV risk markers, a pattern that is reversed in remission. %ULN IGF-1 levels strongly predict these features. Given the known increased CV risk of active acromegaly, these findings suggest that of these factors insulin resistance is most strongly related to disease activity and potentially to the increased CV risk of active acromegaly.
Literature
1.
go back to reference Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674CrossRefPubMed Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674CrossRefPubMed
2.
go back to reference Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly [see comments]. J Clin Endocrinol Metab 83(10):3419–3426PubMed Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly [see comments]. J Clin Endocrinol Metab 83(10):3419–3426PubMed
3.
go back to reference Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed
4.
go back to reference Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendocrinology 83(3–4):211–217CrossRefPubMed Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A (2006) Acromegaly and the cardiovascular system. Neuroendocrinology 83(3–4):211–217CrossRefPubMed
5.
go back to reference Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41(1):95–102CrossRefPubMed Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41(1):95–102CrossRefPubMed
6.
go back to reference Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972–1978CrossRefPubMed Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972–1978CrossRefPubMed
7.
go back to reference Reyes-Vidal C, Fernandez JC, Bruce JN, Crisman C, Conwell IM, Kostadinov J, Geer EB, Post KD, Freda PU (2014) Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab 99(11):4124–4132CrossRefPubMed Reyes-Vidal C, Fernandez JC, Bruce JN, Crisman C, Conwell IM, Kostadinov J, Geer EB, Post KD, Freda PU (2014) Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab 99(11):4124–4132CrossRefPubMed
8.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed
9.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22(9):1462–1470CrossRefPubMed
10.
go back to reference Freda PU, Shen W, Reyes-Vidal CM, Geer EB, Arias-Mendoza F, Gallagher D, Heymsfield SB (2009) Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon X-ray absorptiometry. J Clin Endocrinol Metab 94(8):2880–2886PubMedCentralCrossRefPubMed Freda PU, Shen W, Reyes-Vidal CM, Geer EB, Arias-Mendoza F, Gallagher D, Heymsfield SB (2009) Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon X-ray absorptiometry. J Clin Endocrinol Metab 94(8):2880–2886PubMedCentralCrossRefPubMed
11.
go back to reference Kim J, Heshka S, Gallagher D, Kotler DP, Mayer L, Albu J, Shen W, Freda PU, Heymsfield SB (2004) Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol 97(2):655–660CrossRefPubMed Kim J, Heshka S, Gallagher D, Kotler DP, Mayer L, Albu J, Shen W, Freda PU, Heymsfield SB (2004) Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol 97(2):655–660CrossRefPubMed
12.
go back to reference Niculescu D, Purice M, Coculescu M (2013) Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. 16(2):168–174CrossRefPubMed Niculescu D, Purice M, Coculescu M (2013) Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. 16(2):168–174CrossRefPubMed
13.
go back to reference Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R (1986) Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 250(3 Pt 1):E269–273PubMed Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R (1986) Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 250(3 Pt 1):E269–273PubMed
14.
go back to reference Karlander S, Vranic M, Efendic S (1986) Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia 29(11):778–783CrossRefPubMed Karlander S, Vranic M, Efendic S (1986) Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia 29(11):778–783CrossRefPubMed
15.
go back to reference Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93(6):2334–2343PubMedCentralCrossRefPubMed Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D (2008) Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93(6):2334–2343PubMedCentralCrossRefPubMed
17.
go back to reference Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3):181–183CrossRefPubMed Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3):181–183CrossRefPubMed
19.
go back to reference Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C (2013) The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 98(1):E51–59CrossRefPubMed Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C (2013) The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 98(1):E51–59CrossRefPubMed
20.
go back to reference O’Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK (1994) Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 78(2):381–386PubMed O’Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK (1994) Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 78(2):381–386PubMed
21.
go back to reference Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30(2):121–130CrossRef Bengtsson BA, Brummer RJ, Eden S, Bosaeus I (1989) Body composition in acromegaly. Clin Endocrinol (Oxf) 30(2):121–130CrossRef
22.
go back to reference Brummer RJ, Lonn L, Kvist H, Grangard U, Bengtsson BA, Sjostrom L (1993) Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur J Clin Invest 23(4):199–205CrossRefPubMed Brummer RJ, Lonn L, Kvist H, Grangard U, Bengtsson BA, Sjostrom L (1993) Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur J Clin Invest 23(4):199–205CrossRefPubMed
23.
go back to reference Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS (2007) Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am 36(1):75–87CrossRefPubMed Jorgensen JO, Moller L, Krag M, Billestrup N, Christiansen JS (2007) Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North Am 36(1):75–87CrossRefPubMed
24.
go back to reference Chaves VE, Junior FM, Bertolini GL (2013) The metabolic effects of growth hormone in adipose tissue. Endocrine 44(2):293–302CrossRefPubMed Chaves VE, Junior FM, Bertolini GL (2013) The metabolic effects of growth hormone in adipose tissue. Endocrine 44(2):293–302CrossRefPubMed
25.
go back to reference Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J (1992) Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 74(5):1012–1019PubMed Moller N, Schmitz O, Joorgensen JO, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J (1992) Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 74(5):1012–1019PubMed
26.
go back to reference Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Farrerons J, Lluch P, Puig T, Wagner AM, Ricart W, Webb SM (2008) Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 159(6):773–779CrossRefPubMed Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Farrerons J, Lluch P, Puig T, Wagner AM, Ricart W, Webb SM (2008) Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 159(6):773–779CrossRefPubMed
27.
go back to reference Lin E, Wexler TL, Nachtigall L, Tritos N, Swearingen B, Hemphill L, Loeffler J, Biller BM, Klibanski A, Miller KK (2012) Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol (Oxf) 77(3):430–438CrossRef Lin E, Wexler TL, Nachtigall L, Tritos N, Swearingen B, Hemphill L, Loeffler J, Biller BM, Klibanski A, Miller KK (2012) Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol (Oxf) 77(3):430–438CrossRef
28.
go back to reference Bengtsson BA, Brummer RJ, Eden S, Bosaeus I, Lindstedt G (1989) Body composition in acromegaly: the effect of treatment. Clin Endocrinol (Oxf) 31(4):481–490CrossRef Bengtsson BA, Brummer RJ, Eden S, Bosaeus I, Lindstedt G (1989) Body composition in acromegaly: the effect of treatment. Clin Endocrinol (Oxf) 31(4):481–490CrossRef
29.
go back to reference Madeira M, Neto LV, de Lima GA, Moreira RO, de Mendonca LM, Gadelha MR, Farias ML (2010) Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporos Int 21(12):2019–2025CrossRefPubMed Madeira M, Neto LV, de Lima GA, Moreira RO, de Mendonca LM, Gadelha MR, Farias ML (2010) Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly. Osteoporos Int 21(12):2019–2025CrossRefPubMed
30.
go back to reference Pirlich M, Schutz T, Ockenga J, Biering H, Gerl H, Schmidt B, Ertl S, Plauth M, Lochs H (2003) Improved assessment of body cell mass by segmental bioimpedance analysis in malnourished subjects and acromegaly. Clin Nutr 22(2):167–174CrossRefPubMed Pirlich M, Schutz T, Ockenga J, Biering H, Gerl H, Schmidt B, Ertl S, Plauth M, Lochs H (2003) Improved assessment of body cell mass by segmental bioimpedance analysis in malnourished subjects and acromegaly. Clin Nutr 22(2):167–174CrossRefPubMed
31.
go back to reference Srikanthan P, Karlamangla AS (2011) Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 96(9):2898–2903CrossRefPubMed Srikanthan P, Karlamangla AS (2011) Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 96(9):2898–2903CrossRefPubMed
32.
go back to reference Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92(4):1479–1484CrossRefPubMed Gibney J, Wolthers T, Burt MG, Leung KC, Umpleby AM, Ho KK (2007) Protein metabolism in acromegaly: differential effects of short- and long-term treatment. J Clin Endocrinol Metab 92(4):1479–1484CrossRefPubMed
33.
go back to reference Loyman TG, Chen Z (2005) Dual energy X-ray absorptiometry. In: Heymsfield, S, Lohman TG, Wang Z, Going SB (eds) Human body composition. Human Kinetics, Champaign, IL, p 63–78 Loyman TG, Chen Z (2005) Dual energy X-ray absorptiometry. In: Heymsfield, S, Lohman TG, Wang Z, Going SB (eds) Human body composition. Human Kinetics, Champaign, IL, p 63–78
34.
go back to reference Ho KK, Gibney J, Johannsson G, Wolthers T (2006) Regulating of growth hormone sensitivity by sex steroids: implications for therapy. Front Horm Res 35:115–128CrossRefPubMed Ho KK, Gibney J, Johannsson G, Wolthers T (2006) Regulating of growth hormone sensitivity by sex steroids: implications for therapy. Front Horm Res 35:115–128CrossRefPubMed
35.
go back to reference Jorgensen JO, Christensen JJ, Vestergaard E, Fisker S, Ovesen P, Christiansen JS (2005) Sex steroids and the growth hormone/insulin-like growth factor-I axis in adults. Horm Res 64(Suppl 2):37–40PubMed Jorgensen JO, Christensen JJ, Vestergaard E, Fisker S, Ovesen P, Christiansen JS (2005) Sex steroids and the growth hormone/insulin-like growth factor-I axis in adults. Horm Res 64(Suppl 2):37–40PubMed
36.
go back to reference Parkinson C, Ryder WD, Trainer PJ (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86(11):5240–5244CrossRefPubMed Parkinson C, Ryder WD, Trainer PJ (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86(11):5240–5244CrossRefPubMed
37.
go back to reference Gibney J, Healy ML, Sonksen PH (2007) The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev 28(6):603–624CrossRefPubMed Gibney J, Healy ML, Sonksen PH (2007) The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev 28(6):603–624CrossRefPubMed
38.
go back to reference Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK (2005) Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289(2):E266–271CrossRefPubMed Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK (2005) Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289(2):E266–271CrossRefPubMed
39.
go back to reference Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK (2005) Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab 90(7):3989–3994CrossRefPubMed Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK (2005) Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab 90(7):3989–3994CrossRefPubMed
40.
go back to reference Damjanovic SS, Petakov MS, Raicevic S, Micic D, Marinkovic J, Dieguez C, Casanueva FF, Popovic V (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85(1):147–154CrossRefPubMed Damjanovic SS, Petakov MS, Raicevic S, Micic D, Marinkovic J, Dieguez C, Casanueva FF, Popovic V (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85(1):147–154CrossRefPubMed
41.
go back to reference Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83(10):3476–3479PubMed Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83(10):3476–3479PubMed
42.
go back to reference Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V, Murphy LJ (2003) Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 58(6):736–742CrossRef Silha JV, Krsek M, Hana V, Marek J, Jezkova J, Weiss V, Murphy LJ (2003) Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 58(6):736–742CrossRef
43.
go back to reference Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8(10):CR685–689PubMed Bolanowski M, Milewicz A, Bidzinska B, Jedrzejuk D, Daroszewski J, Mikulski E (2002) Serum leptin levels in acromegaly—a significant role for adipose tissue and fasting insulin/glucose ratio. Med Sci Monit 8(10):CR685–689PubMed
44.
go back to reference Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363–372CrossRefPubMed Vilar L, Naves LA, Costa SS, Abdalla LF, Coelho CE, Casulari LA (2007) Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract 13(4):363–372CrossRefPubMed
45.
go back to reference Boero L, Manavela M, Merono T, Maidana P, Gomez Rosso L, Brites F (2012) GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol (Oxf) 77(4):579–585CrossRef Boero L, Manavela M, Merono T, Maidana P, Gomez Rosso L, Brites F (2012) GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin Endocrinol (Oxf) 77(4):579–585CrossRef
46.
go back to reference Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978CrossRefPubMed Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19(4):972–978CrossRefPubMed
47.
go back to reference Derfalvi B, Igaz P, Fulop KA, Szalai C, Falus A (2000) Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro. Cell Biol Int 24(2):109–114CrossRefPubMed Derfalvi B, Igaz P, Fulop KA, Szalai C, Falus A (2000) Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro. Cell Biol Int 24(2):109–114CrossRefPubMed
48.
go back to reference Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523–527CrossRefPubMed Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94(2):523–527CrossRefPubMed
Metadata
Title
IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition
Authors
Tirissa J. Reid
Zhezhen Jin
Wei Shen
Carlos M. Reyes-Vidal
Jean Carlos Fernandez
Jeffrey N. Bruce
Jane Kostadinov
Kalmon D. Post
Pamela U. Freda
Publication date
01-12-2015
Publisher
Springer US
Published in
Pituitary / Issue 6/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-015-0657-2

Other articles of this Issue 6/2015

Pituitary 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.